SG11201509580PA - Heterocyclic compounds as hedgehog signaling pathway inhibitors - Google Patents
Heterocyclic compounds as hedgehog signaling pathway inhibitorsInfo
- Publication number
- SG11201509580PA SG11201509580PA SG11201509580PA SG11201509580PA SG11201509580PA SG 11201509580P A SG11201509580P A SG 11201509580PA SG 11201509580P A SG11201509580P A SG 11201509580PA SG 11201509580P A SG11201509580P A SG 11201509580PA SG 11201509580P A SG11201509580P A SG 11201509580PA
- Authority
- SG
- Singapore
- Prior art keywords
- signaling pathway
- heterocyclic compounds
- pathway inhibitors
- hedgehog signaling
- hedgehog
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1309508.8A GB201309508D0 (en) | 2013-05-28 | 2013-05-28 | Compounds |
| PCT/GB2014/051623 WO2014191737A1 (en) | 2013-05-28 | 2014-05-28 | Heterocyclic compounds as hedgehog signaling pathway inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201509580PA true SG11201509580PA (en) | 2015-12-30 |
Family
ID=48784788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201509580PA SG11201509580PA (en) | 2013-05-28 | 2014-05-28 | Heterocyclic compounds as hedgehog signaling pathway inhibitors |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9579319B2 (en) |
| EP (1) | EP3004078A1 (en) |
| JP (1) | JP2016520115A (en) |
| KR (1) | KR20160013188A (en) |
| CN (1) | CN105431421A (en) |
| AU (1) | AU2014272867A1 (en) |
| BR (1) | BR112015029495A2 (en) |
| CA (1) | CA2912208A1 (en) |
| EA (1) | EA201592108A1 (en) |
| GB (1) | GB201309508D0 (en) |
| HK (1) | HK1217492A1 (en) |
| IL (1) | IL242515A0 (en) |
| MX (1) | MX2015016451A (en) |
| PH (1) | PH12015502611A1 (en) |
| SG (1) | SG11201509580PA (en) |
| WO (2) | WO2014191736A1 (en) |
| ZA (1) | ZA201508396B (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105985320B (en) * | 2015-02-11 | 2018-10-26 | 复旦大学 | Benzyl phthalazine compound and its preparation method and application |
| CN105985321B (en) * | 2015-02-11 | 2018-10-26 | 复旦大学 | Pyrazoles phthalazine compound and its preparation method and application |
| CN105985319B (en) * | 2015-02-11 | 2019-02-26 | 复旦大学 | Aryl phthalazine compound and its preparation method and application |
| CA2987067A1 (en) * | 2015-06-05 | 2016-12-08 | Dana-Farber Cancer Institute, Inc. | Compounds and methods for treating cancer |
| US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
| EP3464272B1 (en) | 2016-06-07 | 2021-12-08 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
| JP2019524678A (en) * | 2016-07-04 | 2019-09-05 | スーチョウ キンター ファーマシューティカルズ インコーポレイテッド | Chiral heterocyclic compound having hedgehog pathway antagonist activity, method for producing the same, and application thereof |
| CN106474147B (en) * | 2016-10-14 | 2022-07-05 | 上海颉隆投资管理有限公司 | Dressing for preventing and controlling human papilloma virus infection and preparation method thereof |
| KR102317480B1 (en) | 2017-03-23 | 2021-10-25 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | Novel heterocyclic derivatives useful as SHP2 inhibitors |
| US11389434B2 (en) | 2017-05-18 | 2022-07-19 | Inserm | Methods and pharmaceutical compositions for the treatment of mast cell diseases |
| CN109734700B (en) * | 2019-01-14 | 2021-09-28 | 中国药科大学 | SMO inhibitor containing benzoyl piperidine structure and preparation method and application thereof |
| IL310264A (en) | 2021-07-21 | 2024-03-01 | Nico Therapeutics Inc | Annulated pyridazine compound |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3567725A (en) | 1968-11-20 | 1971-03-02 | Merck & Co Inc | Process for preparation of 1h-imidazo-(4,5-b)pyrazin-2-ones |
| US4022779A (en) | 1974-07-25 | 1977-05-10 | E. R. Squibb & Sons, Inc. | Amino derivatives of pyrido(3,4-b)pyrazine carboxylic acids and esters |
| GB1513432A (en) * | 1974-07-25 | 1978-06-07 | Squibb & Sons Inc | Pyridopyrazines |
| KR100443893B1 (en) * | 1996-01-15 | 2004-10-15 | 얀센 파마슈티카 엔.브이. | Angiogenesis inhibitor pyridazine amine |
| CZ296000B6 (en) * | 1997-06-24 | 2005-12-14 | Janssen Pharmaceutica N. V. | Thiadiazolyl pyridazine derivatives, process of their preparation and pharmaceutical compositions in which the derivatives are comprised |
| SG154433A1 (en) * | 2004-06-30 | 2009-08-28 | Janssen Pharmaceutica Nv | Phthalazine derivatives as parp inhibitors |
| EP1900731A1 (en) * | 2006-09-07 | 2008-03-19 | Bayer Schering Pharma Aktiengesellschaft | N-(1-Phthalazin-1-yl-piperidin-4-yl)-amides as EP2-receptor modulators |
| JP5603770B2 (en) * | 2007-05-31 | 2014-10-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | CCR2 receptor antagonist and use thereof |
| KR20100044829A (en) | 2007-08-06 | 2010-04-30 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | Aminopyrazole amide derivative |
| CA2723042A1 (en) | 2008-04-29 | 2009-11-05 | Eli Lilly And Company | Disubstituted phthalazine hedgehog pathway antagonists |
| US20100041663A1 (en) * | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
| FR2938537B1 (en) * | 2008-11-14 | 2012-10-26 | Sanofi Aventis | ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF |
| PT2358698E (en) | 2008-11-17 | 2012-10-24 | Lilly Co Eli | Tetrasubstituted pyridazine as hedgehog pathway antagonists |
| EP2358703B1 (en) | 2008-11-17 | 2013-12-25 | Eli Lilly and Company | Tetrasubstituted pyridazines hedgehog pathway antagonists |
| AR077014A1 (en) * | 2009-06-19 | 2011-07-27 | Lilly Co Eli | COMPOUND DERIVED FROM FTALAZINE 1,4-DISPOSED, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND USE TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF CANCER |
-
2013
- 2013-05-28 GB GBGB1309508.8A patent/GB201309508D0/en not_active Ceased
-
2014
- 2014-05-28 US US14/893,691 patent/US9579319B2/en not_active Expired - Fee Related
- 2014-05-28 BR BR112015029495A patent/BR112015029495A2/en not_active Application Discontinuation
- 2014-05-28 JP JP2016516237A patent/JP2016520115A/en active Pending
- 2014-05-28 CN CN201480042367.8A patent/CN105431421A/en active Pending
- 2014-05-28 WO PCT/GB2014/051622 patent/WO2014191736A1/en active Application Filing
- 2014-05-28 EP EP14728247.9A patent/EP3004078A1/en not_active Withdrawn
- 2014-05-28 MX MX2015016451A patent/MX2015016451A/en unknown
- 2014-05-28 AU AU2014272867A patent/AU2014272867A1/en not_active Abandoned
- 2014-05-28 SG SG11201509580PA patent/SG11201509580PA/en unknown
- 2014-05-28 EA EA201592108A patent/EA201592108A1/en unknown
- 2014-05-28 CA CA2912208A patent/CA2912208A1/en not_active Abandoned
- 2014-05-28 WO PCT/GB2014/051623 patent/WO2014191737A1/en active Application Filing
- 2014-05-28 KR KR1020157036722A patent/KR20160013188A/en not_active Application Discontinuation
-
2015
- 2015-11-09 IL IL242515A patent/IL242515A0/en unknown
- 2015-11-13 ZA ZA2015/08396A patent/ZA201508396B/en unknown
- 2015-11-23 PH PH12015502611A patent/PH12015502611A1/en unknown
-
2016
- 2016-05-17 HK HK16105627.2A patent/HK1217492A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2912208A1 (en) | 2014-12-04 |
| US9579319B2 (en) | 2017-02-28 |
| EP3004078A1 (en) | 2016-04-13 |
| GB201309508D0 (en) | 2013-07-10 |
| HK1217492A1 (en) | 2017-01-13 |
| JP2016520115A (en) | 2016-07-11 |
| MX2015016451A (en) | 2016-08-03 |
| BR112015029495A2 (en) | 2017-07-25 |
| WO2014191737A1 (en) | 2014-12-04 |
| WO2014191736A1 (en) | 2014-12-04 |
| IL242515A0 (en) | 2016-02-01 |
| ZA201508396B (en) | 2019-04-24 |
| PH12015502611A1 (en) | 2016-02-29 |
| AU2014272867A1 (en) | 2015-12-10 |
| US20160113928A1 (en) | 2016-04-28 |
| EA201592108A1 (en) | 2016-07-29 |
| CN105431421A (en) | 2016-03-23 |
| KR20160013188A (en) | 2016-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1253099A1 (en) | Heterocyclic amides as kinase inhibitors | |
| HK1217492A1 (en) | Heterocyclic compounds as hedgehog signaling pathway inhibitors | |
| HUE043398T2 (en) | Glycosidase inhibitors | |
| IL265496A (en) | Bace1 inhibitors | |
| EP2982666A4 (en) | Heterocyclic compound | |
| IL245379A0 (en) | N-acylimino heterocyclic compounds | |
| HK1221465A1 (en) | Novel heterocyclic compounds | |
| EP3018126A4 (en) | Heterocyclic compound | |
| EP2980089A4 (en) | Heterocyclic compound | |
| EP2961403A4 (en) | Heterocyclic inhibitors of the sodium channel | |
| EP2982670A4 (en) | Heterocyclic compound | |
| IL244347A0 (en) | N-acylimino heterocyclic compounds | |
| HK1217654A1 (en) | Furanone compounds as kinase inhibitors |